|
Christopher Piercy
Chairman
Chris Piercy is an experienced investor, entrepreneur, and manager who has
founded and managed, as CEO or Chairman, a number of biotechnology, nanotechnology,
hi- tech, and consulting companies in the U.S., Europe, and Asia.
He has founded
or was a member of the founding team of a number of companies. For example:
Connective Therapeutics, Connetics, (NASDAQ 'CNCT' - a biopharmaceutical company);
Coleman Consulting (a management consulting group for the global Fortune 1000);
Global Connect (a Japan based international telecom) and a number of others,
primarily in the biotechnology and nanotechnology industries. Mr. Piercy has
been working in the biotechnology sector since 1985, when he joined the pioneering
biotechnology company, Cetus Corporation (now Chiron; NASDAQ 'CHIR'). Mr. Piercy
has been a partner at SVIC , a Palo Alto Silicon Valley based early stage venture
capital firm.
Chris Piercy
studied Molecular Genetics and History at U.C. Berkeley and business at Harvard
Business School, and the Stanford Business School Advanced Management Program.
Mr. Piercy serves as an Advisory board member of NASA Ames Institute of Science and Technology (NAIST); serves on the Advisory Board for the University of California Center for Adaptive Optics; industry advisory board for the National Science Foundation Center for Biophotonics Science and Technology (CBST). Chris Piercy is also a founding board member of the Silicon Valley Nanobiotechnology Organization in Los Altos; National Nanotechnology Initiative Regional Nanotechnology Coordination Committee, Northern California Nanotechnology Initiative, NanoSIG, and the Nanotechnology Industry Organization. He also serves on the boards of a number of cutting edge high
technology companies and is active in various other business, biotechnology
and nanotechnology organizations, in the US and abroad. Mr. Piercy is an author
of a number of studies and books on biotechnology and nanotechnology. He is
the inventor of developing or patented technologies and his scientific work
(at UC Berkeley, Stanford University, and for the biopharmaceutical industry)
has contributed to the development of a number of novel therapeutic drugs,
diagnostic and research products, the Human Genome Project, and has been published
in such leading journals as Nature, Science, Proceedings of the National
Academy of Sciences, etc.
|